Subsequent Events	6 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events On July 1, 2025, the Company entered into the Merger Agreement with Concentra and Merger Sub. The Merger Agreement provides for, among other things: (i) the acquisition of all of the Company’s outstanding shares of Common Stock by Concentra through the Offer by Concentra, for the Offer Price and (ii) after the completion of the Offer and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, the Merger with the Company surviving the Merger. There can be no assurance that the Merger will be completed as the closing of the Offer is subject to various conditions, including the tender of the Common Stock representing at least a majority of the total number of voting Common Stock (including any shares held by Concentra), the availability of at least $82.0 million of cash (net of transaction costs, wind-down costs and other liabilities) at closing (the Closing Net Cash), and other customary closing conditions. The Merger is expected to close in August 2025 if all closing conditions are satisfied. If the Merger is effected, all current and ongoing operations will be terminated and the Company will be delisted from the Nasdaq Stock Market LLC. The Company's obligation to file periodic reports under the Exchange Act will terminate, and the Company will be privately held.

Subsequent Events

6 Months Ended

Jun. 30, 2025

Note 14. Subsequent Events

On July 1, 2025, the Company entered into the Merger Agreement with Concentra and Merger Sub. The Merger Agreement provides for, among other things: (i) the acquisition of all of the Company’s outstanding shares of Common Stock by Concentra through the Offer by Concentra, for the Offer Price and (ii) after the completion of the Offer and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, the Merger with the Company surviving the Merger. There can be no assurance that the Merger will be completed as the closing of the Offer is subject to various conditions, including the tender of the Common Stock representing at least a majority of the total number of voting Common Stock (including any shares held by Concentra), the availability of at least $82.0 million of cash (net of transaction costs, wind-down costs and other liabilities) at closing (the Closing Net Cash), and other customary closing conditions. The Merger is expected to close in August 2025 if all closing conditions are satisfied. If the Merger is effected, all current and ongoing operations will be terminated and the Company will be delisted from the Nasdaq Stock Market LLC. The Company's obligation to file periodic reports under the Exchange Act will terminate, and the Company will be privately held.

IGM Biosciences, Inc. 10-Q